Electric Tumor Treatment Field Therapy – Commercial and Individual Exchange Medical Policyopen_in_new

UnitedHealthcare covers FDA‑approved tumor treatment field (TTF) therapy only for supratentorial glioblastoma—newly diagnosed (histologically confirmed) and radiologically confirmed recurrent GBM—when criteria are met, and considers TTF unproven/not medically necessary for non‑GBM tumors, for rGBM used with concurrent systemic therapy, or when required criteria are not met. Key requirements: for ndGBM completed debulking surgery and radiation plus ongoing single‑agent temozolomide; for rGBM device as sole therapy after initial chemotherapy; KPS ≥60 or ECOG ≤2; documented counseling and ≥18 hours/day device use; initial approval 3 months with continuation requiring an MRI within 2 months showing no progression and documentation of ongoing eligibility and device use.

"Newly diagnosed, histologically confirmed supratentorial glioblastoma (ndGBM) — use of FDA‑approved electric tumor treatment field (TTF) devices when ALL of the following are met: debulking surgery..."